Rhythm Property Plant And Equipment Gross vs Cash Analysis

RYTM Stock  USD 59.92  0.02  0.03%   
Rhythm Pharmaceuticals financial indicator trend analysis is much more than just breaking down Rhythm Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Rhythm Pharmaceuticals is a good investment. Please check the relationship between Rhythm Pharmaceuticals Property Plant And Equipment Gross and its Cash accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.

Property Plant And Equipment Gross vs Cash

Property Plant And Equipment Gross vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Rhythm Pharmaceuticals Property Plant And Equipment Gross account and Cash. At this time, the significance of the direction appears to have strong relationship.
The correlation between Rhythm Pharmaceuticals' Property Plant And Equipment Gross and Cash is 0.68. Overlapping area represents the amount of variation of Property Plant And Equipment Gross that can explain the historical movement of Cash in the same time period over historical financial statements of Rhythm Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Rhythm Pharmaceuticals' Property Plant And Equipment Gross and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Property Plant And Equipment Gross of Rhythm Pharmaceuticals are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Property Plant And Equipment Gross i.e., Rhythm Pharmaceuticals' Property Plant And Equipment Gross and Cash go up and down completely randomly.

Correlation Coefficient

0.68
Relationship DirectionPositive 
Relationship StrengthSignificant

Property Plant And Equipment Gross

Cash

Cash refers to the most liquid asset of Rhythm Pharmaceuticals, which is listed under current asset account on Rhythm Pharmaceuticals balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Rhythm Pharmaceuticals customers. The amounts must be unrestricted with restricted cash listed in a different Rhythm Pharmaceuticals account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.
Most indicators from Rhythm Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Rhythm Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.At this time, Rhythm Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 26th of November 2024, Tax Provision is likely to grow to about 592.2 K, while Enterprise Value Over EBITDA is likely to drop (16.16).
 2021 2022 2023 2024 (projected)
Reconciled Depreciation1.2M1.7M1.8M1.1M
Interest Income447K4.0M13.2M13.8M

Rhythm Pharmaceuticals fundamental ratios Correlations

0.660.790.950.78-0.8-0.790.80.840.760.671.00.810.350.970.150.950.830.40.771.00.420.980.860.320.61
0.660.960.510.41-0.58-0.960.280.560.950.950.620.650.420.620.640.630.920.840.770.640.40.630.92-0.180.98
0.790.960.670.61-0.64-0.970.520.640.950.920.770.720.420.780.530.770.970.770.890.780.410.770.97-0.040.92
0.950.510.670.82-0.77-0.650.840.80.610.510.970.690.110.95-0.130.90.720.150.720.960.390.950.760.520.43
0.780.410.610.82-0.74-0.620.790.780.530.380.790.650.260.72-0.110.870.730.140.830.780.350.770.690.490.33
-0.8-0.58-0.64-0.77-0.740.74-0.53-0.97-0.7-0.62-0.79-0.66-0.22-0.66-0.12-0.81-0.78-0.32-0.68-0.79-0.49-0.74-0.77-0.18-0.56
-0.79-0.96-0.97-0.65-0.620.74-0.48-0.72-0.95-0.9-0.76-0.75-0.44-0.73-0.56-0.77-0.99-0.78-0.9-0.77-0.45-0.76-0.980.03-0.92
0.80.280.520.840.79-0.53-0.480.60.360.230.830.560.260.84-0.080.790.560.130.680.820.190.840.60.540.2
0.840.560.640.80.78-0.97-0.720.60.670.580.830.690.330.690.120.860.760.330.680.830.320.770.760.250.52
0.760.950.950.610.53-0.7-0.950.360.670.990.720.680.430.70.560.740.940.770.770.740.450.690.92-0.180.96
0.670.950.920.510.38-0.62-0.90.230.580.990.630.610.40.620.620.630.880.80.670.650.430.60.87-0.30.98
1.00.620.770.970.79-0.79-0.760.830.830.720.630.790.310.980.10.950.80.360.761.00.410.980.840.370.56
0.810.650.720.690.65-0.66-0.750.560.690.680.610.790.420.760.320.760.760.50.720.80.610.80.770.180.59
0.350.420.420.110.26-0.22-0.440.260.330.430.40.310.420.270.650.480.420.650.350.33-0.050.310.4-0.370.46
0.970.620.780.950.72-0.66-0.730.840.690.70.620.980.760.270.110.90.770.370.750.970.410.980.830.370.56
0.150.640.53-0.13-0.11-0.12-0.56-0.080.120.560.620.10.320.650.110.120.470.950.320.120.090.10.46-0.640.72
0.950.630.770.90.87-0.81-0.770.790.860.740.630.950.760.480.90.120.830.370.80.950.380.930.840.290.58
0.830.920.970.720.73-0.78-0.990.560.760.940.880.80.760.420.770.470.830.710.930.820.470.80.990.020.88
0.40.840.770.150.14-0.32-0.780.130.330.770.80.360.50.650.370.950.370.710.570.380.220.360.71-0.490.88
0.770.770.890.720.83-0.68-0.90.680.680.770.670.760.720.350.750.320.80.930.570.770.410.790.920.230.69
1.00.640.780.960.78-0.79-0.770.820.830.740.651.00.80.330.970.120.950.820.380.770.410.990.850.350.59
0.420.40.410.390.35-0.49-0.450.190.320.450.430.410.61-0.050.410.090.380.470.220.410.410.440.46-0.040.39
0.980.630.770.950.77-0.74-0.760.840.770.690.60.980.80.310.980.10.930.80.360.790.990.440.850.380.55
0.860.920.970.760.69-0.77-0.980.60.760.920.870.840.770.40.830.460.840.990.710.920.850.460.850.080.87
0.32-0.18-0.040.520.49-0.180.030.540.25-0.18-0.30.370.18-0.370.37-0.640.290.02-0.490.230.35-0.040.380.08-0.35
0.610.980.920.430.33-0.56-0.920.20.520.960.980.560.590.460.560.720.580.880.880.690.590.390.550.87-0.35
Click cells to compare fundamentals

Rhythm Pharmaceuticals Account Relationship Matchups

Rhythm Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets308.5M187.1M329.5M382.5M332.7M186.9M
Other Current Liab377K12.0M29.5M32.9M47.5M49.9M
Total Current Liabilities24.4M18.0M43.4M39.8M55.2M58.0M
Total Stockholder Equity281.0M166.5M284.2M264.3M169.8M137.7M
Property Plant And Equipment Net5.7M5.0M4.3M3.4M2.1M2.4M
Net Debt(58.7M)(97.8M)(56.7M)(125.7M)(58.8M)(61.8M)
Retained Earnings(325.3M)(459.3M)(528.9M)(710.1M)(894.7M)(850.0M)
Accounts Payable10.4M4.9M5.7M4.8M4.9M4.4M
Cash62.3M100.9M59.2M127.7M60.1M50.8M
Non Current Assets Total6.1M5.4M21.1M28.2M24.5M25.7M
Cash And Short Term Investments292.5M172.8M294.9M333.3M275.8M169.6M
Common Stock Shares Outstanding36.4M44.1M49.6M52.1M57.7M39.3M
Short Term Investments230.2M71.9M235.6M205.6M215.8M142.5M
Liabilities And Stockholders Equity308.5M187.1M329.5M382.5M332.7M203.9M
Non Current Liabilities Total3.1M2.6M1.9M78.4M107.8M113.2M
Other Current Assets9.9M8.9M12.4M11.8M8.9M5.8M
Other Stockholder Equity606.3M625.8M813.0M974.4M1.1B1.1B
Total Liab27.5M20.5M45.4M118.2M163.0M171.1M
Property Plant And Equipment Gross5.7M5.0M4.3M3.4M6.2M6.5M
Total Current Assets302.4M181.7M308.4M354.2M308.3M178.6M
Accumulated Other Comprehensive Income(752K)49K(1K)(92K)134K140.7K
Net Tangible Assets281.0M166.5M279.5M256.4M294.8M163.0M
Capital Surpluse606.3M625.8M813.0M974.4M1.1B1.2B
Other Assets403K2.2M12.1M17.0M19.5M20.5M
Property Plant Equipment5.7M3.2M2.8M2.2M2.5M2.3M
Retained Earnings Total Equity(325.3M)(459.3M)(528.9M)(710.1M)(639.1M)(607.1M)
Net Invested Capital281.0M166.5M284.2M264.3M169.8M244.6M
Net Working Capital278.0M163.7M265.0M314.4M253.1M261.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Rhythm Pharmaceuticals is a strong investment it is important to analyze Rhythm Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rhythm Pharmaceuticals' future performance. For an informed investment choice regarding Rhythm Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.32)
Revenue Per Share
1.863
Quarterly Revenue Growth
0.478
Return On Assets
(0.46)
Return On Equity
(1.48)
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.